Bluejay Diagnostics established a government distribution Partnership with Lovell and paid a one-time $5,500 setup fee. Lovell receives exclusive rights for federal procurements requiring or favoring SDVOSB status, while open-market rights are non-exclusive, giving investors a defined route to government customers after FDA clearance or other required authorization.
Key Highlights
- Lovell must remit payment after receiving funds from federal customers, while overdue undisputed amounts accrue interest at the lesser of 18% annually or the lawful maximum.
- The agreement can end immediately under specified sanctions, bankruptcy, judgment or operational-discontinuation conditions.
- Agreement dated September 1, 2026 gives Lovell non-exclusive rights to list and resell products in open-market government procurements.
- Lovell is the sole distributor for qualifying federal set-aside opportunities involving the Department of Veterans Affairs, Department of Defense and Indian Health Service.
Exclusive Federal Access and Commercial Terms
The agreement dated September 1, 2026 gives Lovell non-exclusive rights to list and resell products in open-market government procurements. It also makes Lovell the sole distributor for qualifying federal set-aside opportunities involving the Department of Veterans Affairs, Department of Defense and Indian Health Service, including specified federal contract vehicles and successors. Product pricing may change with written notice, while federal catalog prices remain fixed for the required catalog period. The company must provide advance notice before proposed increases and can submit price increase requests within the limits of the agreement. Lovell must pay undisputed invoices under the agreement’s payment terms.
Co-Marketing and Termination Provisions
The agreement begins with an initial term and renews automatically for successive annual periods unless either party gives timely written notice of non-renewal. Either side may terminate immediately if the other is suspended, excluded or sanctioned under a healthcare program, enters Bankruptcy proceedings, permanently stops operations or faces a final non-appealable judgment exceeding $100,000 that materially impairs performance. A party may also terminate after an uncured breach following written notice. The agreement was signed on September 1, 2026, and Bluejay Diagnostics (NASDAQ: BJDX)’ report was signed on September 8, 2026, by President and Chief Executive Officer Neil Dey.



Please wait processing your request...